Myelodysplastic Syndromes: Updates and Nuances

Myelodysplastic syndrome (MDS) is a heterogeneous, clonal stem cell disorder of the blood and marrow typically diagnosed based on the presence of persistent cytopenia(s), dysplastic cells, and genetic markers. Common issues that arise in the clinical management include difficulty confirming MDS diag...

Full description

Saved in:
Bibliographic Details
Published inThe Medical clinics of North America Vol. 101; no. 2; p. 333
Main Author Dao, Kim-Hien T
Format Journal Article
LanguageEnglish
Published United States 01.03.2017
Subjects
Bone Marrow Cells - cytology
Chromatin Assembly and Disassembly - genetics
DNA Methylation - genetics
Hematologic Tests
Humans
Mutation
Myelodysplastic Syndromes - diagnosis
Myelodysplastic Syndromes - genetics
Myelodysplastic Syndromes - physiopathology
Myelodysplastic Syndromes - therapy
Prognosis
RNA Splicing - genetics
Therapy-related myelodysplastic syndrome
Blood and marrow transplant
Anemia
Azacitidine
Myelodysplastic syndrome
Online AccessGet more information

Cover

More Information
Summary:Myelodysplastic syndrome (MDS) is a heterogeneous, clonal stem cell disorder of the blood and marrow typically diagnosed based on the presence of persistent cytopenia(s), dysplastic cells, and genetic markers. Common issues that arise in the clinical management include difficulty confirming MDS diagnosis, lack of a standard approach with novel agents in MDS, and few prospective long-term, randomized controlled MDS clinical studies to guide allogeneic blood and marrow transplant. With the recent genetic characterization of MDS, certain aspects of these issues will be better addressed by integrating genetic data into clinical study design and clinical practice.
ISSN:1557-9859
DOI:10.1016/j.mcna.2016.09.006